AbCellera Biologics (ABCL) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

AbCellera Biologics

NasdaqGS•Healthcare•Biotechnology

$12.63-0.10(-0.01%)Market closed

Market Cap

$3.86B

P/S

58.3x

P/B

4.3x

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

How this company scores

AverageMetricSide Score: 50/100

Strongest: Growth (19/25); weakest: Profitability (7/25).

Profitability7/25

Growth19/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality9/25

Strengths

Growing revenueInterest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 18.3x5y range 11.3x – 26.4x

Currently above its 5-quarter median.

P/S · 58.3x5y range 4.7x – 58.3x

Currently above its 19-quarter median.

P/B · 4.3x5y range 0.6x – 5.7x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $3.86B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $66.17M
Q. Revenue: $4.05M
TTM EBITDA: $-206.08M
TTM Op. Income: $-225.15M
Q. Op. Income: $-62.78M
TTM Net Income: $-164.66M
Q. Net Income: $-55.43M
EPS: $-0.18
Shares Out.: $305.56M

$66.17M in TTM revenue grew 101.3% YoY, reaching $4.05M last quarter. TTM EBITDA of $-206.08M and TTM operating income of $-225.15M show growth is flowing through to the bottom line. However, net income is negative at $164.66M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 101% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1377.5%
Op. Margin: -1550.0%
Net Margin: -1368.6%

Op. margin of -1550.0% is down 1259.8% YoY — costs are rising relative to revenue. Net margin at -1368.6% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 58.3x
P/B Ratio: 4.3x

P/S of 58.3x and P/B of 4.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.31B
Cash: $120.06M
Long-Term Debt: N/A
Book Value: $896.02M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $25.92M
TTM Free Cash Flow: $-119.67M
FCF Margin: -180.8%
FCF / Net Income: 0.7

TTM FCF of $-119.67M on $25.92M in operating cash flow. The FCF / Net Income ratio of 0.7x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 14% — an improving trend.